InterCure (NASDAQ:INCR) Trading Down 0.2% – Should You Sell?

InterCure Ltd. (NASDAQ:INCR)’s share price dropped 0.2% during mid-day trading on Thursday . The stock traded as low as $5.23 and last traded at $5.24. Approximately 5,220 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 44,050 shares. The stock had previously closed at $5.25.

Analyst Ratings Changes

Separately, Weiss Ratings raised InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

InterCure Trading Down 0.2%

The stock has a 50-day moving average of $4.97 and a two-hundred day moving average of $4.56. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The company has a market cap of $57.33 million, a P/E ratio of 34.93 and a beta of 1.42.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.